Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Saved in:
| Title: | Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. |
|---|---|
| Authors: | Subbiah, Vivek1 (AUTHOR), Hu, Mimi I.2 (AUTHOR), Mansfield, Aaron S.3 (AUTHOR), Taylor, Matthew H.4 (AUTHOR), Schuler, Martin5 (AUTHOR), Zhu, Viola W.6 (AUTHOR), Hadoux, Julien7 (AUTHOR), Curigliano, Giuseppe8,9 (AUTHOR), Wirth, Lori10 (AUTHOR), Gainor, Justin F.10 (AUTHOR), Alonso, Guzman11 (AUTHOR), Adkins, Douglas12 (AUTHOR), Godbert, Yann13 (AUTHOR), Ahn, Myung-Ju14 (AUTHOR), Cassier, Philippe A.15 (AUTHOR), Cho, Byoung Chul16 (AUTHOR), Lin, Chia-Chi17 (AUTHOR), Zalutskaya, Alena18 (AUTHOR), Barata, Teresa19 (AUTHOR), Trask, Peter20 (AUTHOR) |
| Source: | Thyroid. Jan2024, Vol. 34 Issue 1, p26-40. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
